Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.